Search - tctmd.com

Displaying 321 - 340 of 427

Sort: Relevancy | Date

Presentation TCT 2016

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Presenter: Patrick T. O'Gara, Alec S. Vahanian, Susheel K. Kodali

October 30, 2016

Presentation TCT 2016

Surgically Implanted Sapien Valve in Mitral Annular Calcium: SITRAL Trial

Presenter: Michael J. Mack, Francesco Maisano, Robert L. Smith

October 30, 2016

Presentation TCT 2016

A Percutaneous Shoehorn via Transbrachial Artery Approach in a Staggering Tavi Procedure With Edwards Sapien 3 Aortic Valve in a Patient With Extremely Calcified Aortic Valve

Presenter: Oscar A. Mendiz, Giora Weisz, Caterina Gandolfo

October 30, 2016

News Conference News PCR London Valves 2016

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

Shelley Wood

September 22, 2016

News Conference News PCR London Valves 2016

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Shelley Wood

September 20, 2016

News Daily News

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Michael O'Riordan

September 20, 2016

News Conference News PCR London Valves 2016

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Shelley Wood

September 20, 2016

News Conference News PCR London Valves 2016

Innovation Overload? Too Many Novel Ideas May Be Holding Back Progress in Transcatheter Mitral Valve Technologies

Shelley Wood

September 19, 2016

News Daily News

TAVR 伴随中风风险：PARTNER 研究深入审查和 CoreValve 数据揭示了机遇和未知

Shelley Wood

September 13, 2016

News Daily News

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Shelley Wood

September 13, 2016

News Daily News

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

Shelley Wood

September 13, 2016

News Conference News ESC 2016

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

Todd Neale

September 02, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for August 2016

Caitlin E. Cox

September 01, 2016

News Daily News

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

L.A. McKeown

August 24, 2016

News Daily News

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Yael L. Maxwell

August 24, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

L.A. McKeown

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Daily News

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Todd Neale

August 01, 2016

News Daily News

Combining Off-Pump CABG and Transaortic TAVR May Be an Option in Some Cases

Todd Neale

July 14, 2016

Advertisement

Intermediate-Risk Studies I: Synthesis of the PARTNER 2A and the Sapien 3 Intermediate-Risk Trials

Surgically Implanted Sapien Valve in Mitral Annular Calcium: SITRAL Trial

A Percutaneous Shoehorn via Transbrachial Artery Approach in a Staggering Tavi Procedure With Edwards Sapien 3 Aortic Valve in a Patient With Extremely Calcified Aortic Valve

Cerebral Protection in TAVR: New Insights, New Questions as First Device Seeks FDA Clearance

TAVR vs SAVR: Limitations and Risks Debated as Transcatheter Therapies Move Into Younger and Lower-Risk Patients

Sapien 3 Approved for Use in Intermediate-Risk Patients in Europe

Leaflet Restriction After TAVR: Two Hospitals Tracking Patients Find Similar Rates of the Phenomenon

Innovation Overload? Too Many Novel Ideas May Be Holding Back Progress in Transcatheter Mitral Valve Technologies

TAVR 伴随中风风险：PARTNER 研究深入审查和 CoreValve 数据揭示了机遇和未知

Stroke Risk With TAVR: In-Depth Review of PARTNER and CoreValve Data Reveals Opportunities and Unknowns

Riesgo de ACV con TAVR: Una Revisión en Profundidad de los Datos del PARTNER y CoreValve Revela Oportunidades e Incógnitas

Valve Thrombosis After TAVR Linked to Larger Device Size, Lack of Warfarin Therapy

TCTMD’s Top 10 Most Popular Stories for August 2016

较低风险患者 TAVR 后生存率优于手术组，没有“风险升高”

TAVR as an Option for Intermediate-Risk Patients: Physicians Respond

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

Mejor Supervivencia y Ausencia de ‘Tendencia de Riesgo’ para TAVR vs Cirugía en Pacientes de Menor Riesgo

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Next-Generation CoreValve Device Receives CE Mark for Use in Intermediate-Risk Patients

Combining Off-Pump CABG and Transaortic TAVR May Be an Option in Some Cases

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content